Bellicum Pharmaceuticals announces successful dosing of first patient cohort with BPX-501
Bellicum Pharmaceuticals announced that the first cohort of patients in the BP-004 trial has completed dosing with the Company’s genetically engineered donor T cells (BPX-501), after receiving a partial T depleted haplo-identical allogeneic hematopoietic stem cell transplant. January 24, 2015